Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome.
Medical School of Hannover, Hannover, Germany.
Annette D
AD
Wagner
Jan
J
Andresen
Michael C
MC
Jendro
Jan L
JL
Hülsemann
Henning
H
Zeidler
D020083:Acquired Hyperostosis Syndrome / Q000188:drug therapy*; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept